International Criminal Court 02 December 2005
Maanweg, 174 http:/ actionlyme.org
2516 AB, The Hague
The Netherlands
Tel: + 31 (0)70 515
8515
Fax: +31 (0)70 515
8555
SCIENTIFIC FRAUD AND BIOWEAPONS-“BARDA”
European Commission
Hearing Office
Rue de la Loi 200
J79 - 05/211
B-1049 Brussels
+32 (0)2 296.95.78
Office of the High Commissioner for Human Rights
United Nations Office at Geneva
1211 Geneva 10, Switzerland
Fax: + 41 22 917 9022
+41 22 917 9011
Dear Sirs,
Yale University (New Haven, CT),
and the “front” the American Lyme Disease Foundation (www.aldf.com),
and it’s twin spin firm Europe’s EUCALB, created a condition of scientific
fraud and racketeering, wherein they changed the testing for Lyme borreliosis
to make it almost undetectable.
The scheme was this:
Lyme is a borreliosis- a relapsing
fever organism. That is, it changes its
out surface proteins such that the antibody panel created by the infected
mammal is useless for the next relapse or mutation in outer surface
components. Think of it as a bacterium
which changes the color of its freckles.
For this reason, the only means to
detect the bug is to look for markers from what is known NOT to change, and
that is, largely, flagellin, or the inner bundle of “muscle” fibers. The little these parasites are, are a small
amount of cell material wrapped around this bundle of muscle, which expands and
contracts, making the bug appear spiral.
They can penetrate cells “end-on” (Malawista, Yale), or tip first. Yale has such an early and accurate test,
patented in the US under 5,618,533.
There is very little difference
between Relapsing Fever borreliosis and Lyme borreliosis. They both actively seek out brain and nerve
tissue (Barbour, The Biology of Borrelia Species, 1986).
The vaccine created by Yale and
SmithKline Belgium never worked, and in fact, suppressed the immune system,
creating a multi-system disease in vaccinated individuals which is quite like
chronic Lyme. The mechanism is
known: Downregulating of immune system
action in response to the fungal-like vaccine, OspA or LymeRIX, or, simply, one
of the freckles in the analogy above.
Now, as you can see, the immune
cells cannot “see” the freckles, and make antibodies.
The only problem is, this freckle,
OspA, or LymeRIX, is a Pam3Cys conformed lipopeptide which is only seen
elsewhere in mycobacteria (leprosy, tuberculosis) or mycoplasmal infections
(infections which have no cell-wall), and in no other bacteria.
Mycoplasmal infections are also
stealth infections that turn off the immune system.
Knowing what we know now, it is
easy to see why Lyme is so devastating.
In my presentation to the US Food and
Drug Administration in January 2001, I told the FDA that LymeRIX appeared to
NOT be “preventing asymptomatic Lyme,” as claimed, but was making people
symptomatic.
This turned out to be more true
than I knew at the time.
SmithKline and Yale reported that
there were no “asymptomatic” Lyme cases in the vaccine-receiving group, while
there were 15 in the placebo group.
That means 15 people out of ~5500
of whom got the placebo – became infected with Lyme, but did not have any
symptoms. (Half the people who are
infected with Lyme have no symptoms, yet will always harbor this latent
infection.)
SmithKline reported that 1/3 of
all people who had the erythema migrans (characteristic Lyme rash). Or, were
bitten by a tick, did not test positive via the bloodwork, but tested positive
via DNA testing for the bug from skin puncture sample of the rash.
The people involved in this crime
of LymeRIX conspired to change the CDC’s official bloodtesting standard so that
they could capture all of the national testing for Lyme, because they were th
only ones licensed to use the false test which was used to qualify
LymeRIX. Those involved were Yale’s L2
Diagnostics, Corixa Corporation (Washington State), and Imugen of Norwood
Massachusetts.
The Corixa patent is US patent No.
6,045,804.
They specify in the body of the
claim of that patent that:
“The present invention provides
a method useful to detect a B. burgdorferi infection in a subject. The method
provided by the invention is particularly useful to discriminate B. burgdorferi
infection from OspA vaccination, although it is sufficiently sensitive and
specific to use in any general Lyme disease screening or diagnostic
application. Thus, the method of the invention is particularly appropriate for
large scale screening or diagnostic applications where only part of the subject
population has been vaccinated or where the vaccination status of the
population is unknown.”
Yale owned the
patent for OspA or LymeRIX (US Patent No. 5,747,294). Corixa’s David Persing own this patent, and he only licensed it
to Yale and Immugen, and later claimed he could not read Western Blots from
either Lyme vaccine trial, 2 years after the publications of the results of
those vaccines trials.
In,
|
1: Clin Infect Dis. 2000 Jul;31(1):42-7. Epub
2000 Jul 17. |
Detection of multiple
reactive protein species by immunoblotting after recombinant outer surface protein
A lyme disease vaccination.
Molloy PJ, Berardi VP, Persing DH, Sigal LH.
Rheumatology Associates of Southeastern Massachusetts, Plymouth, MA, USA.
Laboratory confirmation of the diagnosis of Lyme disease is based on the
detection of an immune response to Borrelia burgdorferi. The serodiagnosis of
B. burgdorferi infection is complex and may be further confounded by the immune
response to the recombinant outer surface protein A (OspA) Lyme disease
vaccine. To describe how the serological response to the recombinant OspA Lyme
disease vaccine affects testing for antibody to B. burgdorferi, 240 specimens
from 80 study subjects were obtained at defined intervals after recombinant
OspA Lyme disease vaccination. Samples were tested by indirect enzyme-linked
immunosorbent assay (ELISA), antibody capture enzyme immunoassay (EIA), and
Western blotting (WB). After recombinant OspA Lyme disease vaccination, ELISA
for 98% of the study subjects revealed reactivity. WB with use of
OspA-containing B. burgdorferi strains as sources of antigens demonstrated
multiple bands. Results of testing with a US Food and Drug
Administration-approved WB kit showed homogeneous reactivity in the molecular
weight region >30 kDa. Testing with OspA-free strains completely eliminated
all vaccine-associated reactivity by both antibody capture EIA and WB. PMID: 10913394 [PubMed - indexed for
MEDLINE]
In the full
text of that report, the authors claim that:
In the case of the
FDA-approved immunoblot test kit, the identification of
discrete bands at molecular weights >30 kDa is often
unreliable or impossible because of the homogeneous
staining in this area, compromising the ability of this
test to diagnose Lyme disease in vaccinated study
subjects. The manufacturer of the only currently
FDA-approved (and released) recombinant OspA Lyme disease
vaccine has suggested that vaccination does not interfere
with serological evaluation of Lyme disease in vaccine
recipients
a statement that is not supported
by the data presented here.
In other words,
they were unable to read the Lyme tests in people who were vaccinated, yet the
two vaccine manufacturers, SmithKline and Connaught, reported 76% and 92% safe
and effective vaccines.
Sigal (author,
above) was the principal investigator for Connaught’s ImmuLyme vaccine (never
came onto the market), yet here he reports that his 92% safe and effective Lyme
vaccine was qualified with data that he could not even read: “ vaccination
does not interfere with serological evaluation of Lyme
disease in vaccine recipientsa statement that is not supported
by the data presented here.”
Sigal could
not read the results, but he reported a 92% safe and effective vaccine.
I hope that is
clear and simple. Clear and simple
scientific FRAUD.
We Lyme
activists got LymeRIX off the market by having people report the adverse events
that the vaccine trial administrators refused to report to the FDA, and later
via the Lyme Disease Foundation’s Karen Forschner (www.lyme.org -
not a spin firm) having found a Tuft’s patent for a new version of LymeRIX, in
which they specify what they know to be potential harmful about LymeRIX, based
on their perception of Lyme as an autoimmune reaction.
Some people
have the hypersensitivity reaction to OspA, which Allen Steere calls Lyme
arthritis, but State University of New York’s Raymond Dattwyler says is
rare. Dattwyler says he sees only about
one such case per year, and states that Allen Steere only has about 40 such
patients, total.
I told the FDA
in a meeting in Bethsda Maryland in Jaunary 2001 that:
http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3680t2.rtf (See page 148 of that transcript- they misspell my last name
as “Dixon.”
“As Dr.
Luft alluded to earlier this morning, the western blot serology from these
unconfirmed lyme cases will need to be reviewed for evidence of other BB
specific bands, and compared to the placebo group by an independent group of
analysts.
If there are any
other specific bands besides OspA the case must be counted as lyme disease in
the presence of symptoms. Note that
there were only two asymptomatic cases in the first year of the vaccine group,
versus 13 of the placebo group, and in the following year there were zero
asymptomatic cases, and 15 asymptomatic cases in the placebo group.
We believe that
these results do not show that the vaccine is effective at preventing
asymptomatic lyme disease, but rather that it is turning asymptomatic lyme
disease into symptomatic cases.
Continued follow-up
on these unconfirmed patients should have been with further western blotting
from one of the CDC recommended strains, and the original case definition,
which would be to look for changing bands, or any other specific bands besides
OspA.
Or maybe one of
these newer antigens D complexing messenger has been developed at SUNY and by
Leonard Siegel.
We already
discussed this earlier. It was
mentioned earlier that an adverse vaccine event can't be distinguished from
vaccine failure. An adverse vaccine
event in a previously infected asymptomatic lyme patient.
An asymptomatic BB
infected adverse LYMErix event case may never be detected until the patient is
vaccinated and symptoms occur, which we think explains the majority of adverse
events regarding LYMErix.
Many previously
infected lyme cases report systemic symptoms after vaccination, and many find
out they had lyme disease after being vaccinated, becoming ill, being tested
for lyme disease, and finding other specific antibodies.
The FDA should,
therefore, not be looking just for arthritis as a potential adverse event, but rather
-- and not to the exclusion of systemic illness.
According to Allan
Steere the rate of asymptomatic infection to symptomatic infection is one to
one. So that for every person walking
around with lyme disease that has symptoms, there is a person walking around
with asymptomatic lyme disease. And we think those people are at the greatest
risk.
Vaccine failure
and exacerbation of asymptomatic infection are identical according to the
patient data collected and on the on line VAERS data base.
The Dressler Dearborne Steere standard
is not a valid criteria for assessing lyme disease, the former CDC criteria of
changing bands is more valid. Until
there is an independent review of the western blot data from the SmithKline
Beecham adult trial, we have no idea how safe this vaccine is, it all needs to
be retabulated.”
All of that turned out to be
completely true, as we later learned.
Therefore, my complaint, and the
risk here, in our US Department of Justice’s refusal to prosecute this crime,
manipulation of data, harm and fraud, is that now the NeoCon Gods of Our
Destiny, have a new proposal to make such “data,” and the conduct of such
frauds, even more secret.
“BARDA”
“Biomedical
Advanced Research and Development
Agency”
What we
learned from Lyme and the secrecy and the fraud, especially by sneeking into a
conference given by Mark Klempner- who will now head a CDC Biohazard Level 4
Lab in Boston – and audiotaping him revealing that there is a genetic
susceptibility to suffer more serious consequences of this fungal like OspA and
mycobacterial exposures, just as there is a genetic susceptibility for black
people to acquire AIDS.
The difference
in the latter is that black people are 5 times more liable to become infected
with HIV and that Nordic peoples have the lowest risk. The link is in the chemokine receptor CCR5.
It isn’t
common knowledge that black people have a greater risk of contracting
AIDS. Our crazy war president tries to
associate AIDS and black people and character flaws. This is the real reason for the denial of care to AIDS
victims. These NeoCons, as I previously
demonstrated to you, believe black people are stupid, and belong in cages
(“Custodial Democracy”).
The NeoCon
Gods of BigPharma frauds, like Yale University and Mark Klempner and all the
people who are privileged to this secret Lyme data- like the sponsors of the
ALDF (Mortimer Zuckerman, and the Bush Walker Weld Walton international
banker/investors)- having failed to create the monopoly on national bloodwork
(Imugen and Yale) because LymeRIX was removed from the market (and we no longer need Dave Persing’s
special Lyme test – US patent 6,045,804), now have a replacement monopoly in
the works.
Setting up
more biotech spin, fraud and abuse.
Lyme patients are accused of everything, from hypochondria to
Munchausen’s by Proxy (they literally have accused us of poisoning our kids).
You must take
a stand. We have no help here. They (Yale staff) threw me in jail and
falsely charged me with being a criminally insane terrorist. I am not exaggerating.
Kathleen M.
Dickson 23 Garden Street, Pawcatuck, CT 06379 http://actionlyme.org
|
|
|
|
|